Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


ACC.17 Overview

No description

John Barlow

on 23 March 2017

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of ACC.17 Overview

BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions.
Powerful new cholesterol drug helps statins slash the risk of heart attack: Medication could save thousands of lives every year
HEART ATTACK DRUGS BOOST New wonder drug can slash risk of heart attack, stroke or death by a QUARTER compared with just statins
ACC topics
of tweets from those of high authority
During unique users mentioned Amgen or Repatha times – leading to over

Mixing new drug with statins can reduce risk of heart attack
Huge advance' in fighting world's biggest killer
New drug that can 'switch off' heart disease could cut death rates by a FIFTH
Repatha outcomes data less than stellar Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements
Did Amgen's Repatha cut CV risks enough to make it cost-effective? Analysts say no
However some trade and financial press in particular aren't yet convinced of the value
Amgen cholesterol drug cuts heart attack, stroke risk but shares fall
Amgen Drug Prevents Heart Attacks, Not Deaths, Disappointing Experts
A Heart Attack-Prevention Drug Disappoints...Wall Street
Praluent's cardiovascular benefit trial ODYSSEY is expected to read out in December 2017
Eyes were also on Repatha's competitors
In light of Fourier data, what future for Alnylam and TMC's PCSK9 inclisiran?
ACC hashtags
A look at the news from the
Repatha reduced the risk of

by 20% compared with standard treatment with statin drugs

A 15% reduction in the risk of the



was seen, which included hospitalisation for unstable angina, coronary revascularisation, heart attack, stroke or cardiovascular death
Repatha reduced the rate of
heart attacks

by 27% and
by 21%
It reduced
stents and heart bypass
procedures by
Words linked to Repatha & Amgen included heart attacks, strokes and events
66th Annual Scientific Session & Expo
Over the three days there were tweets about ACC.17
That's 702 tweets an hour!
Social media is becoming a bigger and bigger part of the news cycle at congresses.
Some of the topics most tweeted about were
and some of the most popular hashtags were
When we look at how all this links together
EBBINGHAUS also received signifigant attention with the ACC themselves choosing to focus on the results - answering a long running debate on the effect of PCSK inhibition on cognition
but there was less discussion of CV death, stents and bypasses
There was plenty of coverage, primarily in more consumer outlets, praising the benefits of Repatha
but to a much lesser extent
2.8 million
The quality of the discussion was high with
Conversation peaked at the time of the
results with tweets
With a wealth of new data planned for Repatha, Amgen has the opportunity to remain the leader in this area. However, there is still work to be done to communicate the implications of the FOURIER trial
Long term studies
Paediatric studies
Diabetes studies
Repatha was closely associated with PCSK9, cholesterol and statins while Praluent was closely associated with Repatha and statins
Maximally reducing LDL-C levels with Repatha , beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularisations
As expected FOURIER stole a lot of the news agenda with highly anticipated results
Full transcript